MI HB6048

Beginning January 1, 2026, the Medical Assistance Program shall cover fertility diagnostic care, intrauterine insemination, and ovulation-enhancing drugs and related medical services for treating infertility, including at least 3 cycles of ovulation-enhancing medication treatment over a recipient's lifetime.

Coverage must be provided without discrimination based on age, ancestry, disability, domestic partner status, gender identity, genetic information, marital status, national origin, race, religion, sex, or sexual orientation.

Within 180 days of enactment, the department shall submit a report to the legislature on whether in-vitro fertilization and fertility preservation services are medically reasonable and necessary, possible coverage methods for fee-for-service and managed care organizations, and required funding allocations.

Defines key terms including infertility (inability to achieve pregnancy after specified timeframes, genetic risk factors, or lack of necessary gametes), fertility diagnostic care, intrauterine insemination, and standard fertility preservation services (including gamete and embryo cryopreservation).

Eligible health care providers include physicians, nurse practitioners, and physician's assistants licensed under Michigan law.